Skip to main content
TISSUE REPAIR LTD logo

TISSUE REPAIR LTD — Investor Relations & Filings

Ticker · TRP ISIN · AU0000180887 ASX Professional, scientific and technical activities
Open in API
Filings indexed 139 across all filing types
Latest filing 2022-05-02 Share Issue/Capital Cha…
Country AU Australia
Listing ASX TRP

About TISSUE REPAIR LTD

https://tissuerepair.com.au/

Tissue Repair Ltd is a clinical-stage biopharmaceutical company focused on the development of advanced wound healing and skin repair agents. The company’s core technology centers on Glucoprime, a proprietary yeast-derived beta-glucan designed to stimulate the innate immune system and accelerate the body's natural healing processes. Its lead candidate, TR-987, is being developed for the treatment of chronic wounds, such as venous leg ulcers, and for use in post-procedural recovery following aesthetic treatments. By targeting the inflammatory phase of wound healing, the technology aims to improve clinical outcomes and reduce recovery times. The company focuses on addressing unmet needs in both the medical wound care and cosmetic dermatology markets through its specialized biological platform.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - TRP 6 pages 27.2KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX, specifically concerning restricted securities where the escrow period has expired or is about to expire. It details the number and type of securities to be quoted, the issue dates, and the status of issued capital following quotation. There is no financial performance data, management discussion, or regulatory certification. The document is an announcement related to capital structure changes, specifically the quotation of shares following escrow release. This fits the category of Share Issue/Capital Change (SHA). The document length is 5422 characters, which is sufficient to contain substantive information about the securities quotation rather than just a brief announcement or report publication notice.
2022-05-02 English
Quarterly Activities/Appendix 4C Cash Flow Report 11 pages 290.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'MARCH 2022 APPENDIX 4C' and provides a detailed quarterly cash flow report and operational update for the period ending 31 March 2022. It includes financial data such as cash position, cash operating outflows, and a summary of use of funds compared to a prospectus. It also contains detailed operational updates on drug development, manufacturing progress, regulatory updates, and clinical trial planning. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The presence of actual financial data and detailed business progress for a quarter aligns with the definition of an Interim / Quarterly Report (IR). The document is not an announcement of a report, nor is it a certification or a brief summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-04-28 English
Notice under ASX Listing Rule 3.10A 1 page 181.6KB
Regulatory Filings Classification · 95% confidence The document is an announcement under ASX Listing Rule 3.10A regarding the release of securities from mandatory escrow. It details the number and type of shares being released and the release date. There is no financial data, no report attached or referenced, and no mention of management changes or voting results. The content is about share capital status but does not announce a new share issue or capital change, rather the release of shares from escrow. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-04-21 English
Change of Director's Interest Notice 3 pages 265.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed information about a director's change in shareholding, including the number of securities held before and after the change, the nature of the change (on-market trade), and the value of the transaction. It references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure related to insider trading or director share transactions. The document does not contain financial statements or company performance data, nor is it an announcement of a report. It is a report of personal share transactions by a company director, which fits the definition of 'Director's Dealing' filings.
2022-03-28 English
Tissue Repair Announces USA Patent Approval 1 page
Regulatory Filings Classification · 95% confidence The document is a short announcement about the approval of a USA patent application by Tissue Repair Limited. It discusses intellectual property milestones, patent application details, and progress on clinical trials. There is no financial data, no mention of annual or quarterly reports, no voting results, no management changes, no earnings information, and no regulatory certifications. The document is clearly an announcement of a corporate milestone related to intellectual property and clinical progress, not a financial or regulatory filing. Given its short length (2084 characters) and content, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2022-03-03 English
Appendix 4D and Half Year Report to 31 December 2021 25 pages 617.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Tissue Repair Ltd Appendix 4D Half-year report' and references the half-year ended 31 December 2021. It contains detailed financial statements including profit or loss, financial position, changes in equity, and cash flows. It also includes a directors' report, auditor's independence declaration, and an independent auditor's review report. The content is comprehensive and covers the company's financial performance and operations for the half-year period, which aligns with the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-02-24 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.